JP2022554276A5 - - Google Patents

Info

Publication number
JP2022554276A5
JP2022554276A5 JP2022525289A JP2022525289A JP2022554276A5 JP 2022554276 A5 JP2022554276 A5 JP 2022554276A5 JP 2022525289 A JP2022525289 A JP 2022525289A JP 2022525289 A JP2022525289 A JP 2022525289A JP 2022554276 A5 JP2022554276 A5 JP 2022554276A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable composition
composition according
approximately
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554276A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/058475 external-priority patent/WO2021087432A1/en
Publication of JP2022554276A publication Critical patent/JP2022554276A/ja
Publication of JP2022554276A5 publication Critical patent/JP2022554276A5/ja
Priority to JP2025108138A priority Critical patent/JP2025129244A/ja
Pending legal-status Critical Current

Links

JP2022525289A 2019-11-01 2020-11-02 Mtorc1モジュレーターを使用する処置方法 Pending JP2022554276A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025108138A JP2025129244A (ja) 2019-11-01 2025-06-26 Mtorc1モジュレーターを使用する処置方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962929449P 2019-11-01 2019-11-01
US62/929,449 2019-11-01
PCT/US2020/058475 WO2021087432A1 (en) 2019-11-01 2020-11-02 Methods of treatment using an mtorc1 modulator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025108138A Division JP2025129244A (ja) 2019-11-01 2025-06-26 Mtorc1モジュレーターを使用する処置方法

Publications (2)

Publication Number Publication Date
JP2022554276A JP2022554276A (ja) 2022-12-28
JP2022554276A5 true JP2022554276A5 (cg-RX-API-DMAC7.html) 2023-09-20

Family

ID=75716349

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525289A Pending JP2022554276A (ja) 2019-11-01 2020-11-02 Mtorc1モジュレーターを使用する処置方法
JP2025108138A Pending JP2025129244A (ja) 2019-11-01 2025-06-26 Mtorc1モジュレーターを使用する処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025108138A Pending JP2025129244A (ja) 2019-11-01 2025-06-26 Mtorc1モジュレーターを使用する処置方法

Country Status (11)

Country Link
US (2) US11723890B2 (cg-RX-API-DMAC7.html)
EP (1) EP4051259A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022554276A (cg-RX-API-DMAC7.html)
CN (1) CN114786660A (cg-RX-API-DMAC7.html)
AU (1) AU2020376950B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022008287A2 (cg-RX-API-DMAC7.html)
CA (1) CA3156436A1 (cg-RX-API-DMAC7.html)
IL (1) IL292612A (cg-RX-API-DMAC7.html)
MX (1) MX2022005215A (cg-RX-API-DMAC7.html)
TW (1) TWI870497B (cg-RX-API-DMAC7.html)
WO (1) WO2021087432A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX389001B (es) 2015-10-23 2025-03-20 Navitor Pharm Inc Moduladores de interacción de sestrina-gator2 y sus usos.
ES3040534T3 (en) 2017-04-26 2025-11-03 Navitor Pharm Inc Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
WO2020086816A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
AU2020376950B2 (en) * 2019-11-01 2026-06-11 Supernus Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
KR20250111125A (ko) * 2022-11-01 2025-07-22 나비토르 파마슈티칼스 인코포레이티드 mTORC1 활성의 조절제 및 이의 용도
WO2026085331A1 (en) 2024-10-16 2026-04-23 Navitor Pharmaceuticals, Inc. Mefluleucin for use in the treatment of suicidal ideations associated with depression

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110368A (en) 1972-07-24 1978-08-29 American Cyanamid Company Hydro substituted prostanoic acids and esters
US4346110A (en) 1981-06-01 1982-08-24 Merrell Toraude Et Compagnie Method for treating depression
JPS61149964A (ja) 1984-12-25 1986-07-08 Canon Inc 電子写真感光体
US4670196A (en) 1985-09-05 1987-06-02 Norton Company Tower packing element
ES2029799T3 (es) 1986-01-24 1992-10-01 Toray Industries, Inc. Derivados de 2,5,6,7 tetranor-4,8-inter-m-fenilen pg12.
GB8827885D0 (en) 1988-11-30 1989-01-05 Wellcome Found Novel heterocyclic pesticidal compounds
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
DE19623142A1 (de) 1996-06-10 1997-12-11 Huels Chemische Werke Ag Enantiomerenangereicherte, durch einen tertiären Kohlenwasserstoffrest substituierte Malonsäuremonoester sowie deren Herstellung
HUP9903916A3 (en) 1996-08-28 2001-06-28 Procter And Gamble Co Cincinna Phosphinic acid amides and pharmaceutical compositions containing the same
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
WO1999055688A1 (en) 1998-04-27 1999-11-04 Warner-Lambert Company Substituted diarylalkyl amides as calcium channel antagonists
BR9907140A (pt) 1998-11-04 2000-10-17 Montell Technology Company Bv Componentes catalìticos sólidos, catalisadores e processo para a (co) polimerização de olefinas ch2=chr.
US6329546B1 (en) 1999-01-12 2001-12-11 Laboratory Of Molecular Biophotonics Caged amino acids
US20030203900A1 (en) 1999-05-18 2003-10-30 Martin Quibell Cysteine protease inhibitors
CZ300834B6 (cs) 1999-06-10 2009-08-19 Warner-Lambert Company Llc Mono- a disubstituované kyseliny 3-propyl-gamma-aminomáselné
KR100833371B1 (ko) 2001-04-27 2008-05-28 젠야쿠코교가부시키가이샤 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
US6787664B2 (en) 2002-09-17 2004-09-07 Warner-Lambert Company Llc Process for preparing single enantiomers of 5,5,5,5′,5′,5′-hexafluoroleucine and protected analogs
AU2002953255A0 (en) 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
US20070212428A1 (en) 2004-06-04 2007-09-13 Mood Management Sciences, Inc. Methods and compositions for treating mood disorder
DE102004053407A1 (de) 2004-11-05 2006-05-11 Bayer Healthcare Ag Acylierte Nonadepsipeptide II
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
MX2007009985A (es) 2005-02-18 2008-03-11 Innodia Inc Diastereoisomeros de 4-hidroxiisoleucina y usos de los mismos.
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
HRP20140975T1 (hr) 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체
CN101573334A (zh) 2006-08-21 2009-11-04 普雷萨药品公司 用于治疗中枢神经系统障碍的多介质转运体抑制剂
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP2069339B1 (en) 2006-09-25 2011-05-18 Wockhardt Research Centre Substituted piperidinophenyl oxazolidinones
TWI397418B (zh) 2006-10-10 2013-06-01 Otsuka Pharma Co Ltd 抗憂鬱劑
RU2009118935A (ru) 2006-10-20 2010-11-27 Мерк энд Ко., Инк. (US) Земещенные имидазолы в качестве модуляторов подтипа 3 бомбезиновых рецепторов
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8431608B2 (en) 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
US8445686B2 (en) 2007-08-27 2013-05-21 Abbvie Inc. 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
WO2010044885A2 (en) 2008-10-17 2010-04-22 Whitehead Institute For Biomedical Research Soluble mtor complexes and modulators thereof
JP2012530116A (ja) 2009-06-19 2012-11-29 レツク・フアーマシユーテイカルズ・デー・デー 脱ハロゲン化なしにハロゲノアルケンを水素化する方法
US20120219596A1 (en) 2009-07-30 2012-08-30 Wendelin Stark Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
CA2786245A1 (en) 2010-01-29 2011-08-04 Boehringer Ingelheim International Gmbh Substituted naphthyridines and their use as syk kinase inhibitors
JP5744021B2 (ja) 2010-06-30 2015-07-01 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
CN102464701B (zh) 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
EP2678037B1 (en) 2011-02-25 2014-12-03 Lonza Ltd Branched linker for protein drug conjugates
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
EP2589383A1 (en) 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP subtype-specific rapamycin analogue for use in treatment of diseases
WO2013142229A1 (en) 2012-03-19 2013-09-26 President And Fellows Of Harvard College Designing novel peptides for inducing fibronectin matrix assembly
EP3202397B1 (en) 2012-08-06 2019-09-25 Pitney Pharmaceuticals Pty Limited Compounds for the treatment of mtor pathway related diseases
US20160002159A1 (en) 2013-02-13 2016-01-07 Neal ZONDLO Perfluoro-tert-butyl hydroxyproline
WO2014145852A2 (en) 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
WO2014201111A1 (en) 2013-06-14 2014-12-18 The Brigham And Women's Hospital, Inc. Treatment of mtor hyperactive related diseases and disorders
US10168338B2 (en) 2014-09-12 2019-01-01 Whitehead Institute For Biomedical Research Methods of identifying modulators of sestrin-gator-2 interaction for modulating mTORC1 activity
MX389001B (es) * 2015-10-23 2025-03-20 Navitor Pharm Inc Moduladores de interacción de sestrina-gator2 y sus usos.
WO2017083823A1 (en) 2015-11-13 2017-05-18 Brandeis University Mtor inhibitors and methods of use thereof
US10512656B2 (en) 2016-04-21 2019-12-24 Baylor College Of Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
ES3040534T3 (en) * 2017-04-26 2025-11-03 Navitor Pharm Inc Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
US10653652B2 (en) 2018-02-08 2020-05-19 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction
WO2020086816A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
US10926803B2 (en) 2019-07-17 2021-02-23 GM Global Technology Operations LLC Four rail front crush structure with load dissemination into eight element support structure
AU2020376950B2 (en) 2019-11-01 2026-06-11 Supernus Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
JP6689441B1 (ja) 2019-11-01 2020-04-28 エヌ・ティ・ティ・コミュニケーションズ株式会社 電子マネー管理システムおよび電子マネー管理方法

Similar Documents

Publication Publication Date Title
CN1132581C (zh) 含米尔塔扎平和一种或多种选择性5-羟色胺再摄取抑制剂的药物组合物
JP2021527092A5 (cg-RX-API-DMAC7.html)
WO2023019138A1 (en) Method of maintaining remission of depressive symptoms
JP2022191257A5 (cg-RX-API-DMAC7.html)
JP2022527398A5 (cg-RX-API-DMAC7.html)
Khurmi et al. Randomized double-blind comparison of gallopamil and propranolol in stable angina pectoris
IL292612A (en) Treatment methods using mtorc1 modulator
JP2021534160A5 (cg-RX-API-DMAC7.html)
JP2022508513A5 (cg-RX-API-DMAC7.html)
CN1141937C (zh) 含有曲马朵的药物组合物用于制备治疗偏头痛或类偏头痛的药物
JPWO2023054732A5 (cg-RX-API-DMAC7.html)
JPH0635382B2 (ja) 抗不安薬としてのフルオキセチンの使用法
EP0277352B1 (de) Synergistische Kombination von Azelastin und Theophyllin oder Azelastin und Beta-Mimetika
JP2006511538A (ja) 非ヌクレオシド系逆転写酵素阻害剤(nnrti)とプロテアーゼ阻害剤などのシトクロムp450の阻害剤とを含む組み合わせの使用
JP2023502053A5 (cg-RX-API-DMAC7.html)
JP2023011549A5 (cg-RX-API-DMAC7.html)
JP2019531286A5 (cg-RX-API-DMAC7.html)
RU2192252C2 (ru) Применение прамипексола в лечении синдрома усталых ног
JP2024545496A5 (cg-RX-API-DMAC7.html)
JP2021512086A5 (cg-RX-API-DMAC7.html)
US20020147206A1 (en) Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
DE60125062T2 (de) Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten
JP2006508118A5 (cg-RX-API-DMAC7.html)
CA2684174A1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson
WO2019004465A1 (ja) ペマフィブラートを含有する医薬